The iStent infinite trabecular micro-bypass system has been approved by the Therapeutic Goods Administration to reduce intraocular pressure in adult patients diagnosed with primary open-angle glaucoma (POAG) currently treated with ocular hypotensive medication.
The device can be implanted with or without cataract surgery.
The iStent infinite includes three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents across a span of up to approximately six clock hours around Schlemm’s canal, the eye’s primary drainage channel. Once in place, the stents are designed to lower intraocular pressure by restoring the natural, physiological outflow of aqueous humor. The iStent infinite has a similar mechanism of action to Glaukos’ two-stent iStent inject W trabecular micro-bypass system.
The iStent infinite is covered by private health insurance.
Visit: glaukos.com
